Canterbury DHB
In the seven schedules, drug dosage is related either to the patient’s actual body weight or by calculating the Body Surface area (BSA). Any dose reduction due to renal dysfunction or obesity is done by the Haematology Pharmacist in conjunction with the Transplant Consultant. See also Cytotoxic Drugs in the Drug Usage section.
Day |
Summary |
|
-8 |
Admit to B6 |
|
-7 |
|
Alemtuzumab 10 mg IV |
-6 |
Fludarabine 30 mg/m2 IV |
Alemtuzumab 10 or 20 mg(1) IV |
-5 |
Fludarabine 30 mg/m2 IV |
Alemtuzumab 10 or 20 mg(1) IV |
-4 |
Fludarabine 30 mg/m2 IV |
|
-3 |
Fludarabine 30 mg/m2 IV |
|
-2 |
Fludarabine 30 mg/m2 IV |
|
-1 |
Melphalan 140 mg/m2 IV |
Start Cyclosporin IV |
0 |
SCT infusion |
|
For more details, refer to:
|
Topic Code: 9544